Furthermore, the combination of Sorafenib and CPSF6 depletion significantly enhanced cytotoxicity and the G1 population and suppressed the expression of c-Myc, pro-PARP and pro-caspase3 compared to sorafenib alone in Hep3B cells, strongly demonstrating the synergistic potential of CPSF6 depletion with sorafenib for liver cancer therapy. This evidence concerns the gene CPSF6 and liver cancer.